In our study, we showed the downregulation of PCDH9 in the 1st group vs. the 2nd group of CLL patients, and further investigations will shed light on the potential role of PCDH9 in CLL. This evidence concerns the gene PCDH9 and B-cell chronic lymphocytic leukemia.